Administration, Oral

• 

  Subject Areas on Research

  • "Inactive" ingredients in oral medications. 
  • "Take your pill": the role and fantasy of pills in modern medicine. 
  • 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). 
  • 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. 
  • A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease. 
  • A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation. 
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. 
  • A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. 
  • A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. 
  • A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group. 
  • A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents. 
  • A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. 
  • A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics. 
  • A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis. 
  • A clinical trial of oral therapy in a rural cholera-treatment center. 
  • A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale. 
  • A comparison of oral and rectal absorption of L-dopa esters in rats and mice. 
  • A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. 
  • A direct correlation of the resolution of pseudophakic cystoid macular edema with acetazolamide therapy. 
  • A meta-analysis of zinc salts lozenges and the common cold. 
  • A mouse bleeding model to study oral anticoagulants. 
  • A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. 
  • A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. 
  • A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. 
  • A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. 
  • A non-experimental study of oral anticoagulation therapy initiation before and after national patient safety goals. 
  • A novel approach to maintain gut mucosal integrity using an oral enzyme supplement. 
  • A novel neurotoxoid vaccine prevents mucosal botulism. 
  • A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. 
  • A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. 
  • A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. 
  • A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. 
  • A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer. 
  • A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. 
  • A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. 
  • A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. 
  • A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. 
  • A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). 
  • A physiologic role for somatostatin 28 as a regulator of insulin secretion. 
  • A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. 
  • A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. 
  • A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. 
  • A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. 
  • A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. 
  • A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. 
  • A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. 
  • A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. 
  • A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. 
  • A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS. 
  • A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation. 
  • A review of the health impacts of barium from natural and anthropogenic exposure. 
  • Abdomen after a Puestow procedure: postoperative CT appearance, complications, and potential pitfalls. 
  • Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. 
  • Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. 
  • Absence of detectable pharmacological effects after oral administration of isoxsuprine. 
  • Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand. 
  • Accurate Dosing of Antiretrovirals at Home Using a Foilized, Polyethylene Pouch to Prevent the Transmission of HIV From Mother to Child. 
  • Acute and chronic dosing of Lepidium meyenii (Maca) on male rat sexual behavior. 
  • Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust. 
  • Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. 
  • Acute oral 18-methoxycoronaridine (18-MC) decreases both alcohol intake and IV nicotine self-administration in rats. 
  • Acyclovir-resistant herpes simplex virus keratouveitis after penetrating keratoplasty. 
  • Adaptation after small bowel resection is attenuated by sialoadenectomy: the role for endogenous epidermal growth factor. 
  • Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. 
  • Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. 
  • Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable. 
  • Adherence to Oral Anticancer Therapeutics in the Gynecologic Oncology Population. 
  • Adherence to Oral Therapy for Urgency Urinary Incontinence: Results from the Anticholinergic Versus Botox Comparison (ABC) Trial. 
  • Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-hour exclusions and association with outcome: data from Get with the Guidelines-Stroke. 
  • Adjuvanted Immunotherapy Approaches for Peanut Allergy. 
  • Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. 
  • Administration of Oral Acetaminophen to Reduce Costs for the Hysterectomy Patient at a Community Hospital. 
  • Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. 
  • Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. 
  • All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. 
  • Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits. 
  • Alteration of digoxin pharmacokinetics by a single dose of quinidine. 
  • Alternating ibuprofen and acetaminophen in the treatment of febrile children: a pilot study [ISRCTN30487061]. 
  • American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. 
  • American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. 
  • An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation. 
  • Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial. 
  • Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. 
  • Anticoagulants. 
  • Anticoagulation Resumption After Stroke from Atrial Fibrillation. 
  • Anticoagulation for coexisting bioprosthetic aortic valve thrombosis and anticoagulant-related bleeding: "A double edge sword". 
  • Anticoagulation strategies for the management of postoperative atrial fibrillation. 
  • Antioxidant response to exercise-induced oxidative stress and protection by vitamin E. 
  • Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. 
  • Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. 
  • Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. 
  • Antithrombotic therapy in atrial fibrillation. 
  • Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5). 
  • Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. 
  • Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. 
  • Antiviral activity of mixed-valence rare earth borotungstate heteropoly blues against influenza virus in mice. 
  • Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. 
  • Apixaban to prevent stroke in patients with atrial fibrillation: a review. 
  • Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Apixaban: an emerging oral factor Xa inhibitor. 
  • Application of antimicrobial stewardship to optimise management of community acquired pneumonia. 
  • Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. 
  • Are Prophylactic Postoperative Antibiotics Necessary for Immediate Breast Reconstruction? Results of a Prospective Randomized Clinical Trial. 
  • Aspirated contrast material contributing to respiratory arrest in a pediatric trauma patient. 
  • Aspirin and dry eye? 
  • Assays for measuring rivaroxaban: their suitability and limitations. 
  • Assessment of Trends in Guideline-Based Oral Anticoagulant Prescription for Patients With Ischemic Stroke and Atrial Fibrillation in China. 
  • Assessment of oral antithrombotic therapy by platelet function testing. 
  • Association Between Gastrointestinal Events and Health Care Resource Utilization Among Patients with Osteoporosis: Analysis of a U.S. Managed Care Population. 
  • Association Between Inappropriately Dosed Anticoagulation Therapy With Stroke Severity and Outcomes in Patients With Atrial Fibrillation. 
  • Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants. 
  • Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. 
  • Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. 
  • Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. 
  • Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase. 
  • Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). 
  • Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. 
  • Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. 
  • Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. 
  • Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction. 
  • Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. 
  • Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. 
  • Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. 
  • Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway. 
  • Behavioral and neural responses to gustatory stimuli delivered non-contingently through intra-oral cannulas. 
  • Behavioral thermoregulation in the rat following the oral administration of ethanol. 
  • Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics. 
  • Bioavailabilities of rectal and oral methadone in healthy subjects. 
  • Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. 
  • Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. Focus on isolated coronary artery bypass grafting and oral irreversible P2Y(12) receptor antagonists. 
  • Blastomycosis. New treatment for an old friend of the Carolinas. 
  • Blending Quality Improvement and Research Methods for Implementation Science, Part II: Analysis of the Quality of Implementation. 
  • Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. 
  • Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). 
  • Breast cancer and estrogen replacement therapy. 
  • Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. 
  • Bupropion SR in the naturalistic treatment of elderly patients with major depression. 
  • Bupropion and Naltrexone in Methamphetamine Use Disorder. 
  • COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial. 
  • COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. 
  • COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies. 
  • CT protocols for acute appendicitis: time for change. 
  • Calcitriol for osteitis fibrosa. 
  • Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). 
  • Cardio-protective effects of carnitine in streptozotocin-induced diabetic rats. 
  • Carisbamate, a novel antiepileptic candidate compound, attenuates alcohol intake in alcohol-preferring rats. 
  • Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. 
  • Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. 
  • Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. 
  • Challenge of coadministering antiretroviral therapy and oral anticoagulants in HIV-positive patients. 
  • Chitosan nanoparticles for oral drug and gene delivery. 
  • Choice of vehicle affects pyraclostrobin toxicity in mice. 
  • Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. 
  • Cholestyramine feeding lowers number of colonic apoptotic cells in rat. 
  • Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. 
  • Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. 
  • Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. 
  • Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study. 
  • Classification and treatment of endothermal heat-induced thrombosis: Recommendations from the American Venous Forum and the Society for Vascular Surgery. 
  • Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review. 
  • Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. 
  • Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. 
  • Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. 
  • Clinical efficacy and immune regulation with peanut oral immunotherapy. 
  • Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. 
  • Clinical isoflurane metabolism by cytochrome P450 2E1. 
  • Clinical outcomes and treatment patterns among Medicare patients with nonvalvular atrial fibrillation (NVAF) and chronic kidney disease. 
  • Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. 
  • Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. 
  • Clinical practice guideline: acute otitis externa. 
  • Clinical significance of perfusion defects by thallium-201 single photon emission tomography following oral dipyridamole early after coronary angioplasty. 
  • Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. 
  • Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. 
  • Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. 
  • Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. 
  • Clopidogrel does not induce fibrinolysis in healthy subjects. 
  • Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke? 
  • Colchicine effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): study protocol for a randomized controlled trial. 
  • Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial. 
  • Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease. 
  • Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. 
  • Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. 
  • Combination chemotherapy in histiocytosis X. 
  • Combination live enteric virus vaccines. 
  • Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease. 
  • Combined Mechanical and Oral Antibiotic Bowel Preparation Reduces Incisional Surgical Site Infection and Anastomotic Leak Rates After Elective Colorectal Resection: An Analysis of Colectomy-Targeted ACS NSQIP. 
  • Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition. 
  • Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. 
  • Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. 
  • Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. 
  • Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. 
  • Comparison of Glucosamine Absorption After Administration of Oral Liquid, Chewable, and Tablet Formulations to Dogs. 
  • Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. 
  • Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. 
  • Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. 
  • Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial). 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. 
  • Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. 
  • Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. 
  • Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. 
  • Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. 
  • Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. 
  • Complexation hydrogels for oral protein delivery: an in vitro assessment of the insulin transport-enhancing effects following dissolution in simulated digestive fluids. 
  • Compliance and persistence with osteoporosis therapies. 
  • Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. 
  • Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil. 
  • Conditioned changes in appetitive and consummatory responses to flavors paired with oral or nutrient reinforcement among adult rats. 
  • Conjunctival pseudotumor caused by herpes simplex virus infection. 
  • Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry's Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry. 
  • Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. 
  • Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. 
  • Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. 
  • Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. 
  • Conversion to oral controlled-release oxycodone from intravenous opioid analgesic in the postoperative setting. 
  • Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer. 
  • Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. 
  • Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. 
  • Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy. 
  • Cost-effectiveness of the oral adsorbent AST-120 versus placebo for chronic kidney disease. 
  • Creatine and cyclocreatine attenuate MPTP neurotoxicity. 
  • Current options in oral antiplatelet strategies during percutaneous coronary interventions. 
  • Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist. 
  • Cutaneous hyalohyphomycosis caused by Acremonium in an immunocompetent patient. 
  • Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics. 
  • D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. 
  • Daily oral consumption of hydrolyzed type 1 collagen is chondroprotective and anti-inflammatory in murine posttraumatic osteoarthritis. 
  • Debromination of the flame retardant decabromodiphenyl ether by juvenile carp (Cyprinus carpio) following dietary exposure. 
  • Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. 
  • Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think Tank. 
  • Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. 
  • Demographic and Clinical Factors Associated With Nonsurgical Osteoarthritis Treatment Among Patients in Outpatient Clinics. 
  • Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). 
  • Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. 
  • Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. 
  • Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study. 
  • Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. 
  • Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid. 
  • Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup. 
  • Diagnosis and Treatment of Rosacea Fulminans: A Comprehensive Review. 
  • Diagnostic and Therapeutic Challenges. 
  • Dietary supplementation with fresh pineapple juice decreases inflammation and colonic neoplasia in IL-10-deficient mice with colitis. 
  • Differences in Preferences Between Clinicians and Patients for the Use and Dosing of Direct Oral Anticoagulants for Atrial Fibrillation. 
  • Difluoroethylamines as an amide isostere in inhibitors of cathepsin K. 
  • Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients. 
  • Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis. 
  • Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. 
  • Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. 
  • Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019? 
  • Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis. 
  • Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort. 
  • Direct oral anticoagulants: a review on the current role and scope of reversal agents. 
  • Direct oral anticoagulants: new drugs and new concepts. 
  • Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. 
  • Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R). 
  • Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. 
  • Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer. 
  • Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators. 
  • Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. 
  • Disposition of amiodarone and its proximate metabolite, desethylamiodarone, in the dog for oral administration of single-dose and short-term drug regimens. 
  • Disposition of nasal, intravenous, and oral methadone in healthy volunteers. 
  • Does distance modify the effect of self-testing in oral anticoagulation? 
  • Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. 
  • Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer. 
  • Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. 
  • Double-blind randomized study comparing brand-name and generic phenytoin monotherapy. 
  • Dual versus triple antithrombotic therapy after percutaneous coronary intervention or acute coronary syndrome in patients with indication for anticoagulation: an updated meta-analysis. 
  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. 
  • Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α. 
  • Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. 
  • EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. 
  • Early administration of oropharyngeal colostrum to extremely low birth weight infants. 
  • Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. 
  • Effect of Diagnosis on Outcomes in the Setting of Enhanced Recovery Protocols. 
  • Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. 
  • Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl). 
  • Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. 
  • Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. 
  • Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. 
  • Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. 
  • Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. 
  • Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. 
  • Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxin. 
  • Effect of di(2-ethylhexyl) phthalate on DNA repair and lipid peroxidation in rat hepatocytes and on metabolic cooperation in Chinese hamster V-79 cells. 
  • Effect of dofetilide on survival in patients with supraventricular arrhythmias. 
  • Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. 
  • Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. 
  • Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT). 
  • Effect of hospital use of oral nutritional supplementation on length of stay, hospital cost, and 30-day readmissions among Medicare patients with COPD. 
  • Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study. 
  • Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. 
  • Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. 
  • Effect of oral pentoxifylline on cystoid macular edema associated with central retinal vein occlusion. 
  • Effect of propranolol as antiadhesive therapy in sickle cell disease. 
  • Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. 
  • Effect of vitamin D supplementation on blood pressure in blacks. 
  • Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. 
  • Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. 
  • Effects of amino acid supplementation on left ventricular remodeling in patients with chronic heart failure with decreased systolic function and diabetes mellitus: rationale and design of a magnetic resonance imaging study. 
  • Effects of an oral growth hormone secretagogue in older adults. 
  • Effects of blackcurrant anthocyanin intake on peripheral muscle circulation during typing work in humans. 
  • Effects of cadmium ingestion and food restriction on energy metabolism and tissue metal concentrations in mallard ducks (Anas platyrhynchos). 
  • Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations. 
  • Effects of iodine supplementation during pregnancy on child growth and development at school age. 
  • Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study. 
  • Effects of short-term administration of glucocorticoids on bone metabolism in healthy elderly men. 
  • Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. 
  • Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. 
  • Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. 
  • Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). 
  • Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). 
  • Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. 
  • Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia. 
  • Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. 
  • Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial. 
  • Efficacy of alendronate in adults with cystic fibrosis with low bone density. 
  • Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. 
  • Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. 
  • Efficacy of provitamin A carotenoids in reversing vitamin A deficiency induced lesions in brain lipids of chicks. 
  • Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting. 
  • Electronic alerts to initiate anticoagulation dialogue in patients with atrial fibrillation. 
  • Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. 
  • Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. 
  • Endophthalmitis following Nd:YAG laser posterior capsulotomy. 
  • Enteric intussusception presenting as a rapidly enlarging mass. 
  • Enzalutamide in metastatic prostate cancer before chemotherapy. 
  • Epithelioid hemangioma responsive to oral propranolol. 
  • Epitope maps of the Escherichia coli heat-labile toxin B subunit for development of a synthetic oral vaccine. 
  • Equal antipyretic effectiveness of oral and rectal acetaminophen: a randomized controlled trial [ISRCTN11886401]. 
  • Evaluation of a simpler technique for in-vivo labelling of red blood cells with 99mTc. 
  • Evaluation of the developmental neuroendocrine and reproductive toxicology of aluminium. 
  • Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex. 
  • Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. 
  • Exceptionally potent antispermatogenic compounds from 8-halogenation of (4aRS,5SR,9bRS)-hexahydroindeno-[1,2-c]pyridines. 
  • Exercise increases muscle GLUT-4 levels and insulin action in subjects with impaired glucose tolerance. 
  • Exploring patient-provider decision-making for use of anticoagulation for stroke prevention in atrial fibrillation: Results of the INFORM-AF study. 
  • Extended Oral Antibiotics and Infection Prophylaxis after a Primary or Revision Total Knee Arthroplasty. 
  • Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. 
  • FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. 
  • FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. 
  • Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. 
  • Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). 
  • Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. 
  • Fish oil feeding modulates leukotriene production in murine lupus nephritis. 
  • Fluvastatin downregulates VEGF-A expression in TNF-α-induced retinal vessel tortuosity. 
  • Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. 
  • Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). 
  • Fungal scleritis after cataract surgery. Successful outcome using itraconazole. 
  • Gallbladder density and iodine concentration in humans during oral cholecystography. A comparison of iopanoic acid and iopronic acid. 
  • Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. 
  • Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. 
  • Genomic correlates of variability in immune response to an oral cholera vaccine. 
  • Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. 
  • Glutamine as indispensable nutrient in oncology: experimental and clinical evidence. 
  • Glycerol administration: alternative method and review. 
  • Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reports. 
  • Guidance for the treatment of deep vein thrombosis and pulmonary embolism. 
  • Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. 
  • HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge. 
  • Hedgehog blockade in steroid-refractory sclerotic chronic graft-versus-host disease. 
  • Helical CT cholangiography with three-dimensional volume rendering using an oral biliary contrast agent: feasibility of a novel technique. 
  • Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. 
  • Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. 
  • Hepatic lysosomal enzymes in young rats fed retinol. 
  • Hexabromonaphthalene contaminants of polybrominated biphenyls: chemical composition and disposition in the rat. 
  • Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. 
  • Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. 
  • How much zidovudine is safe for children with advanced HIV? 
  • How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. 
  • Hypokalemia before induction of anesthesia and prevention by beta 2 adrenoceptor antagonism. 
  • Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. 
  • Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. 
  • Imidazo[5,1-f][1,2,4]triazin-2-amines as novel inhibitors of polo-like kinase 1. 
  • Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes. 
  • Immunology in the Clinic Review Series; focus on allergies: immunotherapy for food allergy. 
  • Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation. 
  • Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. 
  • Impaired insulin response after oral but not intravenous glucose in heart- and liver-transplant recipients. 
  • Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes. 
  • Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron. 
  • Improved neurodevelopmental outcomes following long-term high-dose oral acyclovir therapy in infants with central nervous system and disseminated herpes simplex disease. 
  • Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. 
  • In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. 
  • In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. 
  • Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. 
  • Induction of labor with oral prostaglandin E2. 
  • Induction of urinary excretion of 3-nitrotyrosine, a marker of oxidative stress, following administration of pyridostigmine bromide, DEET (N,N-diethyl-m-toluamide) and permethrin, alone and in combination in rats. 
  • Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. 
  • Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. 
  • Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. 
  • Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication. 
  • Initial platelet activity may predict efficacy after chronic oral glycoprotein IIb/IIIa blockade: should we still consider uniform treatment regimens? 
  • Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). 
  • Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. 
  • Inotropic therapy for heart failure: an evidence-based approach. 
  • International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. 
  • International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. 
  • International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. 
  • Interventions to promote adherence with oral agents. 
  • Intestinal alkaline phosphatase prevents metabolic syndrome in mice. 
  • Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial. 
  • Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. 
  • Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. 
  • Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. 
  • Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. 
  • Iron Deficiency Anemia in Pregnancy. 
  • Iron deficiency: lessons from anemic mice. 
  • Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. 
  • Is it safe to use intravenous verapamil to treat a patient who is taking oral verapamil? 
  • Is newer better? Propafenone versus quinidine for conversion of atrial fibrillation. 
  • Isavuconazole for treatment of rare invasive fungal diseases. 
  • Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation. 
  • Isoflurane alters the kinetics of oral cyclosporine. 
  • Isolated thrombocytopenia associated with oral terbinafine. 
  • Janus kinase inhibitors for atopic dermatitis: a promising treatment modality. 
  • Juvenile arthritis and autoimmunity to type II collagen. 
  • Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. 
  • Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor. 
  • Laryngeal transplantation in the setting of cancer: a rat model. 
  • Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. 
  • Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. 
  • Licorice-associated reversible cerebral vasoconstriction with PRES. 
  • Lidocaine lollipop as single-agent anesthesia in upper GI endoscopy. 
  • Limited utility of repeated vital sign monitoring during initiation of oral propranolol for complicated infantile hemangioma. 
  • Locomotor and sensorimotor performance deficit in rats following exposure to pyridostigmine bromide, DEET, and permethrin, alone and in combination. 
  • Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. 
  • Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. 
  • Long-term mutagenicity studies with chloroform and dimethylnitrosamine in female lacI transgenic B6C3F1 mice. 
  • Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials. 
  • Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 
  • Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. 
  • Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. 
  • Mammary gland morphology in Sprague-Dawley rats following treatment with an organochlorine mixture in utero and neonatal genistein. 
  • Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. 
  • Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. 
  • Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation. 
  • Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). 
  • Management of anticoagulation agents in trauma patients. 
  • Management of patients with confirmed and presumed mucous membrane pemphigoid undergoing entropion repair. 
  • Management of urgent invasive procedures in patients treated with direct oral anticoagulants: An observational registry analysis. 
  • Managing new oral anticoagulants in the perioperative and intensive care unit setting. 
  • Managing oral anticoagulant therapy. 
  • Mandated radiologist-performed electronic order entry: effect on CT oral contrast administration. 
  • Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial. 
  • Measures of adherence to oral hypoglycemic agents at the primary care clinic level: the role of risk adjustment. 
  • Mechanical bowel preparation for gynecologic laparoscopy: a prospective randomized trial of oral sodium phosphate solution vs single sodium phosphate enema. 
  • Medical safety in the care of the person with end-stage kidney disease. 
  • Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh. 
  • Menstrual cycle effects on caffeine elimination in the human female. 
  • Metabolic profiling of PPARalpha-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation. 
  • Metformin prevents tobacco carcinogen--induced lung tumorigenesis. 
  • Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. 
  • Methotrexate treatment for sarcoid-associated panuveitis. 
  • Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. 
  • Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. 
  • Monitoring oral anticoagulant therapy in patients with lupus anticoagulants. 
  • Monitoring platelet inhibition during chronic oral platelet glycoprotein IIb/IIIa blockade: are we missing something? 
  • Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. 
  • Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. 
  • Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer. 
  • Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. 
  • Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report. 
  • Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. 
  • N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. 
  • NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. 
  • Nadolol in the treatment of central serous retinopathy. 
  • Naltrexone disposition in man after subcutaneous administration. 
  • Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. 
  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. 
  • Neuroprotective effects of creatine administration against NMDA and malonate toxicity. 
  • Neurotoxicity of ethyl methacrylate in rats. 
  • New and emerging disease modifying therapies for multiple sclerosis. 
  • New oral anticoagulant-induced bleeding: clinical presentation and management. 
  • New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. 
  • Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. 
  • Nicotine increases size and severity of experimental choroidal neovascularization. 
  • Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation. 
  • Non-vitamin K antagonist oral anticoagulants in cardioversion of atrial fibrillation: a network meta-analysis. 
  • Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. 
  • Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. 
  • Novel oral anticoagulants after acute coronary syndromes. 
  • Novel oral anticoagulants and reversal agents: Considerations for clinical development. 
  • Novel oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis. 
  • Novel oral anticoagulants: implications in the perioperative setting. 
  • Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. 
  • Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. 
  • Ocular penetration of 5-fluorocytosine. 
  • Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. 
  • Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. 
  • One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. 
  • Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome. 
  • Open-label maintenance after milk oral immunotherapy for IgE-mediated cow's milk allergy. 
  • Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease. 
  • Oral Chemotherapy Metric Performance in Quality Oncology Practice Initiative Practices: Updated Trends and Analysis. 
  • Oral Coadministration of an Intramuscular DNA/Modified Vaccinia Ankara Vaccine for Simian Immunodeficiency Virus Is Associated with Better Control of Infection in Orally Exposed Infant Macaques. 
  • Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. 
  • Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. 
  • Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure. 
  • Oral Macrolides for the Dermatologic Manifestations of Blau Syndrome. 
  • Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. 
  • Oral activated charcoal prevents experimental cerebral malaria in mice and in a randomized controlled clinical trial in man did not interfere with the pharmacokinetics of parenteral artesunate. 
  • Oral adherence in adults with acute myeloid leukemia (AML): results of a mixed methods study. 
  • Oral and Inhaled Ribavirin Treatment for Respiratory Syncytial Virus Infection in Lung Transplant Recipients. 
  • Oral antibiotics to prevent postoperative urinary tract infection: a randomized controlled trial. 
  • Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. 
  • Oral anticoagulation for subclinical atrial tachyarrhythmias detected by implantable cardiac devices: an international survey of the AF-SCREEN Group. 
  • Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs? 
  • Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. 
  • Oral antihypertensive trial design and analysis under the pediatric exclusivity provision. 
  • Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. 
  • Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice. 
  • Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. 
  • Oral factor Xa inhibitors for the long-term management of ACS. 
  • Oral feeding with pig peripheral lymphocytes decreases the xenogeneic delayed type hypersensitivity reaction in galactosyltransferase knockout mice. 
  • Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. 
  • Oral glutamine enhances heat shock protein expression and improves survival following hyperthermia. 
  • Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial. 
  • Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. 
  • Oral hydration rotavirus diarrhoea: a double blind comparison of sucrose with glucose electrolyte solution. 
  • Oral immunogenicity of the plant proteinase bromelain. 
  • Oral ketoconazole for prevention of postoperative penile erection: a placebo controlled, randomized, double-blind trial. 
  • Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. 
  • Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. 
  • Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial. 
  • Oral nicotine solution for smoking cessation: a pilot tolerability study. 
  • Oral ondansetron pharmacokinetics: the effect of chemotherapy. 
  • Oral platelet IIb/IIIa inhibitors: from attractive theory to clinical failures. 
  • Oral sazetidine-A, a selective α4β2* nicotinic receptor desensitizing agent, reduces nicotine self-administration in rats. 
  • Oral sumatriptan for acute migraine. 
  • Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis. 
  • Oral toxicity of the cyclic polyethers--12-crown-4, 15-crown-5, and 18-crown-6--in mice. 
  • Oral transforming growth factor-alpha enhances jejunal mucosal recovery and electrical resistance in piglet rotavirus enteritis. 
  • Oral transmucosal fentanyl citrate as an anaesthetic premedication when dosed to an opioid effect vs total opioid consumption. 
  • Oral typhoid vaccine Ty21a. 
  • Oral vaccine models: multiple delivery systems employing tetanus toxoid. 
  • Orally Inhaled Drug Particle Transport in Computerized Models of Laryngotracheal Stenosis. 
  • Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. 
  • Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results. 
  • Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. 
  • Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry. 
  • Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. 
  • Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). 
  • Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). 
  • Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics Study. 
  • PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. 
  • Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies. 
  • Parameters for lithium treatment are critical in its enhancement of fracture-healing in rodents. 
  • Parenteral administration of oral medications in lung transplant recipients: An underrecognized problem. 
  • Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. 
  • Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. 
  • Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial. 
  • Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. 
  • Patient-centered medical homes and oral anticoagulation therapy initiation. 
  • Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. 
  • Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation. 
  • Patterns of antihypertensive treatment in patients with acute severe hypertension from a nonneurologic cause: Studying the Treatment of Acute Hypertension (STAT) registry. 
  • Patterns of oral anticoagulation use with cardioversion in clinical practice. 
  • Patterns of prednisone use during pregnancy in women with rheumatoid arthritis: Daily and cumulative dose. 
  • Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report. 
  • Pelvic inflammatory disease. 
  • Pentoxifylline increases retinal capillary blood flow velocity in patients with diabetes. 
  • Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). 
  • Perioperative management of patients on chronic antithrombotic therapy. 
  • Perioperative management of patients receiving new oral anticoagulants: an international survey. 
  • Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. 
  • Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. 
  • Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. 
  • Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. 
  • Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy. 
  • Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. 
  • Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. 
  • Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. 
  • Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. 
  • Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. 
  • Pharmacokinetic studies: their role in determining therapeutic efficacy of agents designed to prevent sudden death. 
  • Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. 
  • Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. 
  • Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. 
  • Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. 
  • Pharmacokinetics of levetiracetam. 
  • Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. 
  • Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. 
  • Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. 
  • Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. 
  • Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation. 
  • Pharmacologically dosed oral glutamine reduces myocardial injury in patients undergoing cardiac surgery: a randomized pilot feasibility trial. 
  • Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists. 
  • Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF. 
  • Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. 
  • Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. 
  • Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. 
  • Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. 
  • Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. 
  • Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. 
  • Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. 
  • Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. 
  • Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. 
  • Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. 
  • Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. 
  • Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. 
  • Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. 
  • Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. 
  • Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. 
  • Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. 
  • Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. 
  • Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. 
  • Phase I trial of pazopanib in patients with advanced cancer. 
  • Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. 
  • Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. 
  • Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. 
  • Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. 
  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. 
  • Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. 
  • Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. 
  • Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. 
  • Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. 
  • Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. 
  • Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. 
  • Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. 
  • Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. 
  • Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. 
  • Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. 
  • Phencyclidine disposition after intravenous and oral doses. 
  • Photo quiz. Rocky Mountain Spotted Fever. 
  • Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans. 
  • Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial. 
  • Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells. 
  • Plasma concentration time course and pharmacological effects of a standardized oral amiodarone dosing regimen in humans. 
  • Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. 
  • Plasma uptake of manganese as affected by oral loads of manganese, calcium, milk, phosphorus, copper, and zinc. 
  • Platelet inhibition with cangrelor in patients undergoing PCI. 
  • Poliovaccine policy--time for a change. 
  • Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents. 
  • Population pharmacokinetics of NNZ-2566 in healthy subjects. 
  • Population pharmacokinetics of sildenafil in extremely premature infants. 
  • Population-based assessment of adverse events associated with long-term glucocorticoid use. 
  • Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. 
  • Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. 
  • Postoperative antibiotic therapy for children with perforated appendicitis: long course of intravenous antibiotics versus early conversion to an oral regimen. 
  • Postoperative oxycodone toxicity in a patient with chronic pain and end-stage renal disease. 
  • Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. 
  • Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. 
  • Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. 
  • Preemptive Oral Acetaminophen for Women Undergoing Total Laparoscopic Hysterectomy. 
  • Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. 
  • Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. 
  • Primary non-adherence to bisphosphonates in an integrated healthcare setting. 
  • Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). 
  • Probiotic supplementation reduces inflammatory profiles but does not prevent oral immune perturbations during SIV infection. 
  • Procainamide administration during pregnancy. 
  • Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. 
  • Programs promoting timely sequential antimicrobial therapy: an American perspective. 
  • Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. 
  • Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. 
  • Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. 
  • Proteolytic activity and immunogenicity of oral bromelain within the gastrointestinal tract of mice. 
  • Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. 
  • Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). 
  • Pyrolytic characteristics, pharmacokinetics, and bioavailability of smoked heroin, cocaine, phencyclidine, and methamphetamine. 
  • Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. 
  • Quantitative thallium-201 single photon emission computed tomography after oral dipyridamole for assessing the presence, anatomic location and severity of coronary artery disease. 
  • Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. 
  • RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. 
  • Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial. 
  • Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. 
  • Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. 
  • Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. 
  • Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. 
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. 
  • Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. 
  • Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. 
  • Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. 
  • Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). 
  • Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. 
  • Re: Researchers make slow headway in managing dry mouth. 
  • Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants and Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase-Reply. 
  • Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. 
  • Reduced GABA synthesis in pyridoxine-dependent seizures. 
  • Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. 
  • Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. 
  • Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist. 
  • Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). 
  • Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). 
  • Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. 
  • Renal hemodynamic and tubular transport effects of nitrendipine. 
  • Response of recurrent medulloblastoma to low-dose oral etoposide. 
  • Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. 
  • Results of a pilot trial comparing prolonged intravenous antibiotics with sequential intravenous/oral antibiotics for children with perforated appendicitis. 
  • Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician. 
  • Reversal agents for non-vitamin K antagonist oral anticoagulants. 
  • Reversing targeted oral anticoagulants. 
  • Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? 
  • Rhythm control in atrial fibrillation. 
  • Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. 
  • Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan　- Insights From GARFIELD-AF. 
  • Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. 
  • Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. 
  • Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention. 
  • Risks versus benefits of different types of long-acting injectable antipsychotics. 
  • Rituximab versus cyclophosphamide for ANCA-associated vasculitis. 
  • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. 
  • Rivaroxaban, an oral direct factor Xa inhibitor. 
  • Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. 
  • Robotically handled whole-tissue culture system for the screening of oral drug formulations. 
  • Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. 
  • Role of cytochrome P4502B6 in methadone metabolism and clearance. 
  • Role of gluten, prednisone, and azathioprine in non-responsive coeliac disease. 
  • SPECT/CT localization of oral radioiodine activity: a retrospective study and in-vitro assessment. 
  • SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation: A Cluster-Randomized Study of Electronic Profiling and Messaging Combined With Academic Detailing for Providers Making Decisions About Anticoagulation in Patients With Atrial Fibrillation. 
  • SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. 
  • Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. 
  • Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. 
  • Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. 
  • Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery. 
  • Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. 
  • Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. 
  • Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials. 
  • Safety and efficacy of weekly oral oltipraz in chronic smokers. 
  • Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults. 
  • Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. 
  • Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. Pediatric Zidovudine Phase I Study Group. 
  • Safety of a peanut oral immunotherapy protocol in children with peanut allergy. 
  • Safety of open food challenges in the office setting. 
  • Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. 
  • Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. 
  • Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. 
  • Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-Get With the Guidelines. 
  • Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. 
  • Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. 
  • Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. 
  • Sensitization to the cardiovascular but not subject-rated effects of oral cocaine in humans. 
  • Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. 
  • Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results. 
  • Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis. 
  • Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. 
  • Side effects of oral misoprostol for the prevention of postpartum hemorrhage: results of a community-based randomised controlled trial in rural India. 
  • Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4+ T Cells. 
  • Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. 
  • Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage. 
  • Single-dose disulfiram does not inhibit CYP2A6 activity. 
  • Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. 
  • Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol. 
  • Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. 
  • Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept. 
  • Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177). 
  • Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. 
  • Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. 
  • Statins and other cholesterol-lowering medications and the presence of glaucoma. 
  • Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers. 
  • Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults. 
  • Steroid Use for Sudden Sensorineural Hearing Loss: A CHEER Network Study. 
  • Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial: Design and rationale. 
  • Stroke prevention in atrial fibrillation: Closing the gap. 
  • Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. 
  • Structure-activity studies of 2,3,4,4a,5,9b-hexahydroindeno[1,2-c]pyridines as antispermatogenic agents for male contraception. 
  • Structure-function relationships of factor Xa inhibitors: implications for the practicing clinician. 
  • Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. 
  • Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. 
  • Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis. 
  • Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. 
  • Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816. 
  • Successful Treatment of Painful Cutaneous Vasculopathy With Rivaroxaban in a Patient With Systemic Lupus Erythematosus. 
  • Successful treatment of Trichosporon mucoides infection with fluconazole in a heart and kidney transplant recipient. 
  • Sunitinib efficacy against advanced renal cell carcinoma. 
  • Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). 
  • Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. 
  • Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonists. 
  • Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. 
  • TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. 
  • Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. 
  • Tamoxifen Improves Glucose Tolerance in a Delivery-, Sex-, and Strain-Dependent Manner in Mice. 
  • Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. 
  • Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. 
  • Testicular germ-cell apoptosis in stressed rats following combined exposure to pyridostigmine bromide, N,N-diethyl m-toluamide (DEET), and permethrin. 
  • Thallium-201 myocardial imaging in patients with coronary artery disease: comparison of intravenous adenosine and oral dipyridamole. 
  • The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. 
  • The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. 
  • The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. 
  • The Role of Elevated Branched-Chain Amino Acids in the Effects of Vertical Sleeve Gastrectomy to Reduce Weight and Improve Glucose Regulation. 
  • The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice. 
  • The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study. 
  • The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease 
  • The common mucosal immune system: from basic principles to enteric vaccines with relevance for the female reproductive tract. 
  • The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor. 
  • The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. 
  • The effect of chronic caffeine administration on serum markers of bone mineral metabolism and bone histomorphometry in the rat. 
  • The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. 
  • The effect of danazol in the treatment of chronic cystic mastitis. 
  • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. 
  • The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors. 
  • The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy. 
  • The effect of oral glycerol on intraventricular pressure in man. 
  • The effect of pentoxifylline on retinal capillary blood flow velocity and whole blood viscosity. 
  • The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. 
  • The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. 
  • The evaluation of drug rechallenge: the casopitant Phase III program. 
  • The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. 
  • The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. 
  • The in vivo antiviral effect of CL246,738 is mediated by the independent induction of interferon-alpha and interferon-beta. 
  • The metabolic effects of calcium supplementation in the elderly. 
  • The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. 
  • The oblique pharyngogram: value in the assessment of dysphagia. 
  • The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration. 
  • The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice. 
  • The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. 
  • The pharmacology of novel oral anticoagulants. 
  • The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. 
  • The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. 
  • The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. 
  • The role of allopurinol and deferoxamine in preventing pressure ulcers in pigs. 
  • The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. 
  • The safety and efficacy of apixaban : where do we stand in 2013? 
  • The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. 
  • Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF. 
  • Therapy for pharyngitis and tonsillitis caused by group A beta-hemolytic streptococci: a meta-analysis comparing the efficacy and safety of cefadroxil monohydrate versus oral penicillin V. 
  • Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. 
  • Therapy with orally administered methoxsalen and ultraviolet A radiation during childhood increases the risk of basal cell carcinoma. The PUVA Follow-up Study. 
  • Time required for elimination of Neisseria gonorrhoeae from the urogenital tract in men with symptomatic urethritis: comparison of oral and intramuscular single-dose therapy. 
  • To bridge or not to bridge: these are the questions. 
  • To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. 
  • Tocolysis for recurrent preterm labor using a continuous subcutaneous infusion pump. 
  • Tocolytic treatment for preterm contractions with and without cervical changes. 
  • Toddler's behavior and its impacts on exposure to polybrominated diphenyl ethers. 
  • Tolerability and Pharmacokinetics of Single Escalating and Repeated Doses of CN-105 in Healthy Participants. 
  • Tolerability of fluoxetine in posttraumatic stress disorder. 
  • Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea. 
  • Toluene abuse embryopathy: longitudinal neurodevelopmental effects of prenatal exposure to toluene in rats. 
  • Topical and oral administration of the natural water-soluble antioxidant from spinach reduces the multiplicity of papillomas in the Tg.AC mouse model. 
  • Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. 
  • Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. 
  • Transdermal versus oral estrogen therapy in postmenopausal smokers: hemodynamic and endothelial effects. 
  • Treatment of adult-onset acute macular retinoschisis in enhanced s-cone syndrome with oral acetazolamide. 
  • Treatment of children symptomatic with human immunodeficiency virus infection. 
  • Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). 
  • Treatment of older patients with atrial fibrillation by morbidity burden. 
  • Treatment of palatal myoclonus with sumatriptan. 
  • Treatment of paroxysmal supraventricular tachycardia with oral diltiazem. 
  • Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. 
  • Treatment outcomes of overactive bladder with combined therapies of botulinum toxin injections and oral agents. 
  • Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease. 
  • Treatment-related biomarkers in pulmonary hypertension patients on oral therapies. 
  • Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020. 
  • Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. 
  • Tumor prevention by 9-cis-retinoic acid in the N-nitroso-N-methylurea model of mammary carcinogenesis is potentiated by the pineal hormone melatonin. 
  • Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. 
  • Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. 
  • Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib). 
  • Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors. 
  • Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. 
  • Use of Direct Oral Anticoagulants in Special Populations. 
  • Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. 
  • Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation. 
  • Use of fluconazole in a patient with documented malabsorption of ketoconazole. 
  • Use of oral ketoconazole to prevent postoperative erections following penile surgery. 
  • Using Plasma and Prothrombin Complex Concentrates. 
  • Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States. 
  • Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation. 
  • Validation of the use of 6,6'-dithiodinicotinic acid as a chromogen in the Ellman method for cholinesterase determinations. 
  • Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. 
  • Variability in oral antibiotic step-down therapy in the management of Gram-negative bloodstream infections. 
  • Vasodilator administration in the presence of beta-adrenergic blockade. 
  • Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. 
  • Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. 
  • Village-based distribution of oral rehydration therapy packets in Bangladesh. 
  • Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group. 
  • Vitamin D Supplementation and Prevention of Type 2 Diabetes. 
  • WITHDRAWN: Oral sumatriptan for acute migraine. 
  • Warfarin or aspirin for recurrent ischemic stroke. 
  • We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity. 
  • What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention? 
  • What is the role of combination drug therapy in the treatment of overactive bladder? ICI-RS 2014. 
  • When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. 
  • Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants? 
  • Wide clinic-level variation in adherence to oral diabetes medications in the VA. 
  • Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. 
  • Zinc and Vitamin Supplementation in an Under-5 Indigenous Population of Guatemala: Influence of Lay Health Promoters in Decreasing Incidence of Diarrhea. 
  • [Computed tomography with thallium-201 and oral dipyridamole in the diagnosis of coronary artery disease]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Allen, Nancy Bates, Professor Emeritus of Medicine, Medicine, Rheumatology and Immunology
  • Levy, Jerrold Henry, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Middleton, John Paul, Professor of Medicine, Medicine, Nephrology
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Immunology
  • Zhong, Xiaoping, Professor of Pediatrics, Immunology